Skip to main content

MDGS

Stock

Performance overview

MDGS Price
Price Chart

Forward-looking statistics

Beta
0.65
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

Sector
Industry
Website
Employees
Market cap

Fundamentals

Enterprise value$72.2M
Revenue$110.3M
Revenue per employee
Profit margin-13.08%
Debt to equity26.08

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$8.70
Dividend per share$1.16
Revenue per share$67.31
Avg trading volume (30 day)$664K
Avg trading volume (10 day)$175K
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield23.33%
PEG Ratio-0.01
Price to sales0.04
P/E Ratio
Enterprise Value to Revenue0.66
Price to book0.13

Upcoming events

Next earnings daySeptember 20, 2021
Next dividend day
Ex. dividend dayDecember 19, 2022

News

Medigus' Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries

Polyrizon Ltd, in which Medigus Ltd (NASDAQ: MDGS) owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal cord injuries. Polyrizon is an Israeli biotech company specializing in intranasal.

Benzinga (July 18, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free